Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: Correlation with histology, serum CA-125 assay, and conventional radiological modalities

Clinical Nuclear Medicine

Volumn 37, Issue 8, 2012, Pages

  Antunovic, Lidija ^a   Cimitan, Marino ^b   Borsatti, Eugenio ^b   Baresic, Tanja ^b   Sorio, Roberto ^b   Giorda, Giorgio ^b   Steffan, Agostino ^b   Balestreri, Luca ^b   Tatta, Rosa ^b   Pepe, Giovanna ^a   Rubello, Domenico ^c   Cecchin, Diego ^d   Canzonieri, Vincenzo ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

18F FDG PET CT; CA 125; conventional imaging; disease recurrence; epithelial ovarian carcinoma

Indexed keywords

CA 125 ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER GRADING; CANCER RELAPSE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; RECURRENT CANCER;

CA-125 ANTIGEN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECURRENCE;

EID: 84863865939     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31825b2583     Document Type: Article

References (28)

1. StatBite. Ovarian cancer: risk of recurrence by stage of diagnosis. J Natl Cancer Inst. 2009;101:1233-1235.
2. Gadducci A, Cosio S, Zola P, et al. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer. 2007;17:21-31. (Pubitemid 46213965)
3. Von Georgi R, Schubert K, Grant P, et al. Post-therapy surveillance and after-care in ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2004;114:228-233. (Pubitemid 38622087)
4. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5:1749-1760.
5. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433-443.
6. Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin. 1999;49:297-320.
7. Javitt MC, Andreotti RF, Lee SI, et al. ACR Appropriateness Criteria: Staging and Follow-up of Ovarian Cancer [ACR Web site]. Reston, VA: American College of Radiology; 2009. Available at: http://www.acr.org/ SecondaryMainMenuCategories/quality-safety/app-criteria/pdf/ ExpertPanelonWomensImaging/StagingandFollowUpofOvarianCancerDoc10.aspx. Accessed January 16, 2012.
8. Prefontaine M, Walker-Dilks C. PET Imaging in Ovarian Cancer: Recommendations. A Quality Initiative of Program in Evidence-Based Care [Cancer Care Ontario (CCO) Web site]. Ontario, Canada: Cancer Care Ontario; 2009. Available at: https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId= 43149. Accessed January 16, 2012.
9. Havrilesky LJ, Kulasingam SL, Matchar DB, et al. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol. 2005;97:183-191. (Pubitemid 40403692)
10. Gu P, Pan LL, Wu SQ, et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma. A systematic review and meta-analysis. Eur J Radiol. 2009;71:164-174.
11. Menzel C, Dobert N, Hamscho N, et al. The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer. Strahlenther Onkol. 2004;180:497-501. (Pubitemid 39062340)
12. 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol. 2005;10:177-181.
13. 18F-FDG PET/CT evaluation of patients with ovarian carcinoma. Nucl Med Commun. 2008;29:1046-1051.
14. Garcia-Velloso MJ, Jurado M, Ceamanos C, et al. Diagnostic accuracy of FDG PET in the follow up of platinum-sensitive epithelial ovarian carcinoma. Eur J Nucl Med Mol Imaging. 2007;34:1396-1405. (Pubitemid 47312579)
15. Pan HS, Lee SL, Huang LW, et al. Combined positron emission tomography computed tomography and tumor markers for detecting recurrent ovarian cancer. Arch Gynecol Obstet. 2011;283:335-341.
16. Nasu K, Abe W, Takai N, Tomonari K, et al. Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment. Arch Gynecol Obstet. 2011;283:1121-1126.
17. Bhosale P, Peungjesada S, Wei W, et al. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer. 2010;20:936-944.
18. Mangili G, Picchio M, Sironi S, et al. Integrated PET/CT as a first-line restaging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging. 2007;34:658-666. (Pubitemid 46669366)
19. Soussan M, Wartski M, Cherel P, et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol. 2008;108:160-165. (Pubitemid 350299439)
20. Fulham MJ, Carter J, Baldey A, et al. The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol. 2009;112:462-468.
21. Nakamoto Y, Saga T, Fujii S. Positron emission tomography application for gynecologic tumors. Int J Gynecol Cancer. 2005;15:701-709. (Pubitemid 41783073)
22. Nanni C, Rubello D, Farsad M, et al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol. 2005;31:792-797. (Pubitemid 41194659)
23. Rieber A, Nussle K, Stohr I, et al. Preoperative diagnosis of ovarian tumors with MR imaging comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am J Roentgenol. 2001;177:123-129. (Pubitemid 32578064)
24. Berger KL, Nicholson SA, Deshdashti F, et al. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol. 2000;174:1005-1008. (Pubitemid 30179992)
25. Torizuka T, Nobezawa S, Kanno T, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D- glucose. Eur J Nucl Med Mol Imaging. 2002;29:797-803.
26. Palomar A, Nanni C, Castellucci P, et al. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels. Mol Imaging Biol. 2012;14:123-129.
27. Fuccio C, Castellucci P, Marzola MC, et al. Noninvasive and invasive staging of ovarian cancer: review of the literature. Clin Nucl Med. 2011;36:889-893.
28. Grassetto G, Groheux D, Marzola MC, et al. FDG PET/CT in ovarian cancer: what about treatment response and prognosis? Clin Nucl Med. 2012;37:54-56.